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Primary hyperparathyroidism is a common condition that aﬀects 0.3% of the general population. Primary and tertiary care
specialists can encounter patients with primary hyperparathyroidism, and prompt recognition and treatment can greatly reduce
morbidity and mortality from this disease. In this paper we will review the basic physiology of calcium homeostasis and then
consider genetic associations as well as common etiologies and presentations of primary hyperparathyroidism. We will consider
emergingtrends indetection andmeasurementofparathyroid hormoneaswell asavailableimagingmodalitiesfortheparathyroid
glands. Surgical indications and approach will be reviewed as well as medical management of primary hyperparathyroidism with
bisphosphonates and calcimimetics.
1.Introduction
Parathyroid hormone is the chief regulator of calcium
homeostasis in the human body. Primary hyperparathy-
roidism (PHPT) results from inappropriate overproduction
of parathyroid hormone from one or many parathyroid
gland(s) and presents with hypercalcemia. It is the third
most common endocrine disorder aﬀecting 0.3% of the
general population, 1%–3% of postmenopausal women and
atotalpopulationincidenceof21.6casesper100,000person-
years [1–3]. PHPT usually occurs as the result of sporadic
parathyroid adenomas or carcinomas but can also be seen in
association with multiple endocrine neoplasias and in rare
genetic syndromes and metabolic diseases [4].
In children, primary hyperparathyroidism is rare. The
most common cause is parathyroid adenoma, usually due
to single gland disease, but severe neonatal hyperparathy-
roidism can also occur due to biallelic mutations in the
calcium sensing receptor gene (CASR) with hypocalciuric
hypercalcemia.
It is important to diﬀerentiate primary from secondary
and tertiary hyperparathyroidism. Secondary hyperparathy-
roidism occurs as a normal response to hypocalcemia
due to diseases aﬀecting the kidney (such as renal tubu-
lar acidosis), liver, intestines, and vitamin D deﬁciency.
In newborn infants, maternal hypoparathyroidism with
hypocalcemia, maternal pseudohypoparathyroidism, and
rare genetic and metabolic syndromes can lead to secondary
hyperparathyroidism. Tertiary hyperparathyroidism occurs
in patients with long-standing secondary hyperparathy-
roidism who develop autonomous PTH production with
hypercalcemia. The most common situation resulting in
tertiary hyperparathyroidism is the patient with secondary
hyperparathyroidism with renal failure who then receives
a renal allograft [5–13]. This paper will focus on primary
hyperparathyroidism.
2.Physiology ofCalciumRegulation
Precise regulation of extracellular and intracellular calcium
is essential for normal physiological processes such as cell
signaling, neuralfunction,muscularfunction(includingcar-
diaccontractility),hormonereleaseandregulation,andbone
metabolism [14]. Parathyroid hormone increases receptor-
mediated tubular reabsorption of calcium in the kidney,2 International Journal of Endocrinology
stimulates release of skeletal calcium stores, upregulates 1-
α- hydroxylase leading to increased 1,25-dihydroxy-vitamin
D production and increased calcium reabsorption from the
gastrointestinal tract [14].
Central to calcium regulation is the calcium-sensing
receptor (CaSR) found primarily in the chief cells of the
parathyroid glands [15]. The CaSR responds to the level
of ionized calcium in the extracellular space and can
upregulate or downregulate the secretion of parathyroid
hormone. Newerevidencesuggeststhat theCaSRplaysa role
independently of parathyroid hormone in the renal tubules
to promote calcium secretion in the face of hypercalcemia
[16].
3.Diagnosisof PrimaryHyperparathyroidism
Primary hyperparathyroidism is diagnosed when PTH is
elevated,inthecontextofhypercalcemia,inapatientwithno
history of renal disease. This is usually a result ofinappropri-
ate parathyroid hormone secretion from one or more of the
parathyroid glands. Biochemical measurement of “intact”
or “total” PTH is performed through immunoradiometric
(IRMA) and immunochemiluminescent assays [17]. These
“second-generation”assays havetraditionally measured both
the 1–84 amino acid sequence of PTH (considered the
biologicallyactivefragment) and otherlargefragments (with
uncertain biological activity), such as the truncated 7–84
amino acid sequence PTH which can accumulate in patients
with renal insuﬃciency [18, 19]. Measurement of PTH [1–
84], widely called the “bioactive” or “3rd-generation assays”
are considered the most precise method for measuring
biologically active PTH using methods such as a two-site
IRMA, a chemiluminescent enzymatic assay, or enzyme-
linked immunosorbent assay (ELISA) [20–23].
4.DifferentialDiagnosis ofElevatedPTH
Parathyroidhormoneelevationcanoccurduetocausesother
than PHPT in patients with normal blood calcium levels.
The most common cause is chronic kidney disease, butother
causes include vitamin D deﬁciency, medications (such as
lithium and thiazide diuretics), and familial hypocalciuric
hypercalcemia(FHH)duetoaheterozygousmutationsofthe
calciumsensing receptor (CASR)gen e[24]. The latter can be
reasonably diﬀerentiated from PHPT based on the calcium
to creatinine clearance ratio of less than 0.01(mmol:mmol)
with 85% sensitivity and 88% speciﬁcity [14, 25]. Vitamin
D levels should be obtained in all patients with increased





Most patients with PHPT have a single adenoma (∼80%
of cases), but multigland disease can occur in 10%–15%
of cases and double adenomas in 4%-5% [27]. Parathyroid
carcinoma is a rare cause (usually less than 1% of patients)
of hyperparathyroidism [28, 29].
Most casesof primary hyperparathyroidism are sporadic,
but there is a higher incidence in patients with a history
of neck irradiation [30], and approximately 5% of cases are
familial as discussed below [27].
6.Genetic CausesofPrimary
Hyperparathyroidism
Mutations in a number of genes are responsible for familial
adenomas or carcinomas presenting with hyperparathy-
roidism, but overall, these represent a minority of cases of
PHPT.
Germline mutations leading to loss of heterozygosity in
the tumour suppressor genes MEN1 (menin) and CDC73
(formerly HRPT2) combined with a second mutation in
somatic cells can increase the predisposition to parathyroid
tumours [31, 32]. Mutations in only somatic cells in these
genes have also been found in sporadic adenomas and
carcinomas, respectively [33]. MEN1 is inherited in an
autosomal dominant manner and isthe most common cause
of familial parathyroid adenomas and a rare cause of familial
carcinomas [34]. Germline mutations in the CDC73 gene
lead to autosomal dominant familial hyperparathyroidism
tumour-jaw syndrome (HPT-JT), parathyroid carcinomas,
and, in some cases, familial isolated hyperparathyroidism
[32, 35–37]. HPT-JT is an autosomal dominant syndrome
ofprimary hyperparathyroidism withparathyroid adenomas
(with or without carcinomas), mandibular or maxillary
ﬁbro-osseous tumors, and renal tumours.
MutationsintheRET proto-oncogene,causinganumber
of diﬀerent endocrine tumour syndromes, can be seen
in MEN2A (associated with parathyroid adenomas) [38–
40]. There are a number of rare cases of MEN4 due
to CDKN1B mutations [41]. Two isolated consanguineous
families, one with nephropathy, deafness, and hyperparathy-
roidism and another with hypophosphatemic rickets and
hyperparathyroidism, have been reported but mutations
were not described in either of the families [42, 43].
Mutations in the parathyroid hormone receptor PTH1R
can be seen in skeletal dysplasias such as Murk Jansen meta-
physeal chondrodysplasis [44], Blomstrand chondrodyspla-
sia [45], Eiken skeletal dysplasias [46] and primary failure of
tootheruption[47]butthusfarare notlinkedtoparathyroid
adenomas or carcinomas [48].
7.ClinicalPresentation
The availability of the automated serum screening panel
has changed the clinical presentation of PHPT. Whereas
prior to the 1970s, this was a disease of recurrent kidney
stones, osteitis ﬁbrosa cystica, neuromuscular dysfunction
characterized by type II muscle cell atrophy [49]a n d
symptomatic hypercalcemia, it has now become an asymp-
tomatic or mildly symptomatic disease detected by the
incidental ﬁnding of hypercalcemia [50]. Of the classical
symptoms, nephrolithiasis is the most common and occursInternational Journal of Endocrinology 3
in 15%–20% of newly diagnosed patients with primary
hyperparathyroidism [51].
PHPT aﬀects compact bone more than trabecular bone
with particular sensitivity in the cortices of long bones
leading to subperiosteal bone resorption (seen as periosteal
e l e v a t i o no np l a i nr a d i o g r a p h y )[ 52]. Although the lumbar
spine is relatively spared in milder forms, some studies
have shown vertebral osteopenia in 15% of patients at
diagnosis which improves with parathyroidectomy [20, 51].
In advanced PHPT, the entire skeleton can be involved
[51]. It is still unclear if PHPT imposes an independent
fracture risk. A review of a large cohort of patients from
the Mayo clinic suggested an overall increased fracture
risk at all sites except the hip [53]. However, the cor-
tical bone thinning eﬀects may be counterbalanced by
increased bone diameter and PTH-mediated periosteal
apposition and the preservation of bone microarchitecture
[54].
Less speciﬁc features of primary hyperparathyroidism
include fatigue, muscle weakness, mild cognitive distur-
bances, hypertension, left ventricular hypertrophy, valvular
calciﬁcation, and cardiovascular mortality [20, 27], but little
data exists on whether these entities are treatable using stan-
dard approaches to manage primary hyperparathyroidism.
8.ManagementofPrimary
Hyperparathyroidism
8.1. Surgical Management. T h eo n l yc u r ef o rp r i m a r yh y p e r -
parathyroidism due to parathyroid adenomas is surgical
resection of the culprit gland or glands. In 2008, The
Third International Workshop on Asymptomatic Primary
Hyperparathyroidism revised the indications for surgery
in asymptomatic patients—these include age less than 50
years, serum calcium 0.25mmol/L above the upper limit of
normal, creatinine clearance <60mL/min, DXA t-score <-
2.5 at any site, and/or previous fragility fracture [58]. An
isolated elevation of 24 hour urine calcium is no longer
an indication for surgery although this measurement may
be necessary to rule out FHH which, although rare, is
most commonly the result of a heterozygous mutation of
the CASR g e n e .T h i si sv e r yd i ﬀerent from neonatal severe
hyperparathyroidism, due to biallelic mutations in the CASR
gene, in which the hypercalcemia is fatal unless recognized
early and subtotal parathyroidectomy is undertaken upon
diagnosis [59]. Surgical treatment may also be the pre-
ferred option to manage pregnant women, children, and
adolescents with hyperparathyroidism [6, 60]. Parathyroid
carcinomas present with high calcium levels and require en
bloc resection of an enlarged gland adherent to adjacent
tissue [61].
Bilateral neck exploration with direct visualization and
identiﬁcation of all abnormal parathyroid glands with
subsequent removal was previously considered the gold
standard of care. Experienced surgeons reported to be able
to identify aﬀected glands in 95% of cases [14]. Unilateral
neck exploration is also highly eﬀective, because PTH has a
short half-life of less than ﬁve minutes and can be measured
after and before adenoma resection to ensure that the
culprit gland has been removed. If levels remain high after
resection of the suspected gland, unilateral neck exploration
can be converted to bilateral neck exploration for direct
visualization and identiﬁcation of missed hypersecreting
parathyroid tissue.
The new standard for most surgeons is preoperative
radiologic localization of adenomas to direct a focused
parathyroidectomy using unilateral neck exploration and
adjunctive intraoperative PTH [65–67]. Intraoperative hand
held gamma probe identiﬁcation of in situ and resected
radiolabelled hyperplastic parathyroid glands can be helpful.
In contrast to sporadic primary hyperparathyroidism,
familial isolated primary hyperparathyroidism (FIHPT) is
characterized by earlier onset disease, higher incidence of
multiglandular involvement and a higher recurrence rate.
Subtotal parathyroidectomy or total excision with auto-
transplantation isrecommendedformulti-glandulardisease.
There is a risk ofpermanent hypocalcemia.It is reported that
many patients with FIHPT return to normocalcemia after
excision of single-gland disease [85]. The use of preoperative
localization and an intraoperative parathyroid hormone
assay permitslimitedresectionofonlyhypersecreting glands.
Limited parathyroidectomy allows successful single-gland
excision in many patients with FIHPT, thus decreasing the
risk of hypoparathyroidism.
Familial hyperparathyroidism associated with MEN1
and MEN2A and familial isolated hyperparathyroidism
are also managed surgically [62–64]. MEN1-associated
hyperparathyroidism patients present earlier than sporadic
patients but with similar symptoms. There is an asymmetri-
calmulti-glandularinvolvementwith agreatersize diﬀerence
between glands than in the hyperplasia of sporadic primary
hyperparathyroidism [86]. The multiple monoclonal tumors
and polyclonal hyperplasias which develop asynchronously
are surgically managed. At exploration, all glands should
be visualized and those normal glands to remain in situ
should be marked for later localization. If one or two normal
glandsarefound,thenonlythehyperplastic glandsshouldbe
removed. If all glands are hyperplastic, total parathyroidec-
tomy and immediate autotransplantation will obviate the
need to subsequently explore a neck scarred from previous
surgery. Generally, the thymus is also removed because of
the possible presence of diseased supernumerary glands
within it. Because unrecognized MEN1 patients should
not be explored, a diagnosis should be obtained before
surgical exploration in patients with hyperparathyroidism
[87, 88].
A minority of MEN2 patients develop hyperparathy-
roidism which, when present, is characteristically mild. At
total thyroidectomy for medullary carcinoma, only hyper-
trophied parathyroid glands should be removed after all are
identiﬁed and marked [89].
Complications from surgery for parathyroidectomy in-
clude persistent hyperparathyroidism if insuﬃcient disease-
causing tissue is removed (which can increase the risk
of fractures), recurrent laryngeal nerve injury, hematoma,
infection, pneumonia, transient or permanent postoper-
ative hypocalcemia, and seizures from hypocalcemia and4 International Journal of Endocrinology
hypomagnesemia [68–71]. Preoperative elevation of serum
alkaline phosphatase may signal the possibility of future
postoperative bone hunger and depressed postoperative
serum calcium levels. Minimally invasive techniques and an
experienced surgeon can reduce the risk of complications
[68, 72].
Hyperparathyroidism is a condition that disproportion-
ately aﬀects older patients who have traditionally been
considered a population at higher operative risk, but several
recent studies have not shown this assumption to be
justiﬁed [73, 74]. Parathyroidectomy should, therefore, be
considered ﬁrst-line therapy even for the frail elderly with
true symptoms of hyperparathyroidism. This must be a joint
decision between the patient, the treating physician, and the
surgeon.
8.2. Identiﬁcation of Suspect Hypersecreting Parathyroid
Glands. Ifa surgeonisplanning anopenparathyroidectomy,
where all 4 glands are directly visualized, no preoperative
imagingmayberequiredandtheuseofpreoperativeimaging
in such circumstances is a matter of personal preference for
the surgeon. However, preoperative imaging is needed if the
surgeon is planning minimally invasive parathyroidectomy,
where only one side of the neck is exposed. Preoperative
imaging can also be helpful in patients with previous neck
surgery in whom scar tissue can make direct visualization
more challenging. Of the available imaging techniques,
the most successful modality is the 99technetium-labelled
sestamibi-single photon emission CT identifying up to
89% of single parathyroid adenomas [55, 56, 90, 91].
99Technetium-labelled sestamibi (99mTc MIBI) is taken up
by parathyroid and thyroid tissue. Uptake is enhanced and
prolonged in adenomatous and hyperplastic parathyroids
[91]. Ultrasound is the second most useful modality and
when used with 99mTc MIBI preoperatively can enhance
adenoma detection rates. Plain computed tomography and
magnetic resonance imaging are less useful except in the
context of persistent or ectopic production [57].
8.3. Revision Surgery. About 5% of patients undergoing
parathyroidectomy will exhibit persistent hypercalcemia
because ofinsuﬃcient removal of disease-causing tissue. The
localization of persistent disease can be anticipated based
upon veriﬁcation of the diagnosis, reviewing pathology
slides and operative reports, interviewing previous surgeons
and by adding localization procedures to those previously
mentioned [92]. Gadolinium-enhanced magnetic resonance
MRI, CT with intravenous contrast, angiography, and selec-
tivevenoussampling forPTH canaidwith localization.Most
missedglandsarefoundintheneck.Somesurgeonsenterthe
operative site lateral to the strap muscles but medial to the
sternocleidomastoid muscle and great neck vessels to avoid a
scarred midline ﬁeld [93]. Upper mediastinal locations may
be approached via an upper-third median sternotomy or by
video-assisted thoracic surgery (VATS). If repeat operation
is unsuccessful, observation and pulsed localization testing
may allow detection as hyperfunctioning parathyroid tissue
enlarges.
8.4.MedicalManagement. Notallcasesofprimaryhyperthy-
roidism require surgical management. For primary hyper-
parathyroidism due to parathyroid adenomas, surgery has
a very high long-term success rate and minimal morbidity.
In contrast, targeted medical therapy with calcimimetics,
such as cinacalcet, is very costly, and both cinacalcet and
bisphosphonates can cause unpleasant side eﬀects. When
the cause of hyperparathyroidism is not primary pathology
in the parathyroid glands, nonsurgical management may be
indicated, and treatment should be aimed at treating the
underlying cause—this principle will be relevant to some
of the neonatal causes and rare syndromes of hyperparathy-
roidism.
In some situations, however, medical management is a
considerationforpatientswithPHPTwho are asymptomatic
from their disease or for patients who are not candidates for
surgery. The cornerstones of medical management include
bone protection with the use of bisphosphonates and
lowering of calcium level with calcimimetics.
Multiple studies have shown that bisphosphonates
improve bone mineral density on DXA scan in patients with
primary hyperparathyroidism. Alendronate has been the
most well-studied bisphosphonate and has shown increases
inbonemineraldensityofthelumbarspineandtheproximal
femur when compared to placebo [75–77]. When using
bisphosphonates, the risk of potential complications, among
them osteonecrosis of the jaw, should be considered [55, 78].
Hormone replacement therapy has also been studied in
postmenopausal women with PHPT and it was found to
have similar bone protective eﬀects as in normocalcemic
postmenopausal women without PHPT [79]. This should
only be used as therapy for PHPT in women who are already
taking HRT for perimenopausal symptoms.
Calcimimetics, like cinacalcet, are designed to allosteri-
cally modify the calcium-sensing receptor, thus sensitizing it
to circulating calcium levels and downregulating PTH tran-
scription, secretion, and parathyroid cell proliferation [80,
81]. Studies show that cinacalcet (versus placebo) eﬀectively
lowers both calcium levels and PTH levels, thus normalizing
the abnormal biochemistry associated with PHPT [82].
There is no signiﬁcant increase in bone mineral density
for patients taking cinacalcet versus placebo as was seen
in the trials with bisphosphonates. However, there was no
signiﬁcant loss of bone mineral density in either the placebo
or the cinacalcet groups [83]. Speciﬁc indications for use
of cinacalcet are limited to situations in which symptomatic
hypercalcemianeedstobecontrolledinapatientwho cannot
undergo surgery. It can sometimes also be used as a trial to
see if lowering calcium improves symptoms in someone who
is considering parathyroidectomy. If preservation of bone
mineral density is the goal of treating asymptomatic PHPT,
then the agent of choice is a bisphosphonate [50].
9.Conclusion
Primary hyperparathyroidism is one of the most common
endocrinological disorders. In rare circumstances, primary
hyperparathyroidism is associated with several familial syn-
dromes. Primary hyperparathyroidism is most frequentlyInternational Journal of Endocrinology 5
identiﬁed incidentally on automated multichannel blood
screening panels and is very often asymptomatic at the time
of diagnosis. Parathyroidectomy remains the deﬁnitive cure
for the disease, and some controversy surrounds the optimal
surgical technique for the procedure. Medical therapy with
the goal of bone preservationi sa no p t i o nf o rp a t i e n t s
without symptoms, and calcimimetics eﬀectively normalize
calcium levels but have speciﬁc indications for use. Medical
therapy may gain popularity for patients with hypercalcemia




DXA: Dual X-ray absorptiometry
ELISA: Enzyme-linked immunosorbent
assay
FHH: Familial hypocalciuric hypercalcemia
FIHPT: Familial isolated primary
hyperparathyroidism
HPT: Hyperparathyroidism
MRI: Magnetic resonance imaging
PHPT: Primary hyperparathyroidism
PTH: Parathyroid hormone
SPECT/MIBI: Sestamibi-single photon emission
computed tomography
VATS: Video-assisted thoracic surgery.
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